Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JCN037 is potent, non-covalent and brain-penetrant inhibitor of EGFR(EGFR, p-wtEGFR and pEGFRvⅢ with IC50 of 2.49 nM, 3.95 nM, 4.48 nM , respectively).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 48.00 | |
5 mg | In stock | $ 147.00 | |
10 mg | In stock | $ 228.00 | |
25 mg | In stock | $ 382.00 | |
50 mg | In stock | $ 568.00 | |
100 mg | In stock | $ 815.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 162.00 |
Description | JCN037 is potent, non-covalent and brain-penetrant inhibitor of EGFR(EGFR, p-wtEGFR and pEGFRvⅢ with IC50 of 2.49 nM, 3.95 nM, 4.48 nM , respectively). |
Targets&IC50 | EGFR:2.49 nM , pEGFRvⅢ:4.48 nM , p-wtEGFR:3.95 nM |
In vivo | Relative to the conventional EGFR TKIs erlotinib and lapatinib, JCN037 displayed potent activity against EGFR amplified/mutant patient-derived cell cultures, significant BBB penetration (2:1 brain-to-plasma ratio), and superior efficacy in an EGFR-driven orthotopic glioblastoma xenograft model. |
Molecular Weight | 376.18 |
Formula | C16H11BrFN3O2 |
CAS No. | 2305154-31-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10 mg/mL (26.58 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
JCN037 2305154-31-6 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR Epidermal growth factor receptor HER1 Inhibitor inhibit JCN 037 JGK-037 ErbB-1 JGK037 JGK 037 JCN-037 inhibitor